Transthyretin Amyloid Cardiomyopathy
📧 Sign up to get email alerts when something new happens for Transthyretin Amyloid Cardiomyopathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-09Clinical Trial Update: EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy [Phase 3]
Phase 3 trial update for EPIC-ATTR evaluating eplontersen in transthyretin amyloid cardiomyopathy in Chinese subjects.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis [Phase 3]
A Phase 3 clinical trial investigating Coramitug (NNC6019-0001) for heart failure due to transthyretin amyloid cardiomyopathy is currently r…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy [Phase 3]
Phase 3 trial evaluating eplontersen for transthyretin amyloid cardiomyopathy in Chinese subjects; status is active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy [Phase 3]
Phase 3 trial update for EPIC-ATTR evaluating eplontersen’s effect on transthyretin reduction and long-term safety in Chinese subjects with …
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy
A post-marketing surveillance study update for Vyndamax (tafamidis) in Korean patients with transthyretin amyloid cardiomyopathy shows the t…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: 24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients [Phase 2]
A 24-month open-label Phase 2 study of inotersen in transthyretin amyloid cardiomyopathy has been terminated. The trial was sponsored by Bri…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis [Phase 2]
This update reports on a Phase 2 study evaluating Novo Nordisk's investigational medicine NNC6019-0001 for safety and effectiveness in trans…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Increased Pacemaker Lower Rate in ATTR Cardiac Amyloidosis [NA]
This clinical trial update reports an observed increase in the lower-rate pacing setting in patients with transthyretin amyloid cardiomyopat…
-
CLINICAL_TRIALS trial_result · 2026-01-30Clinical Trial Update: Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM) [Phase 1]
Phase 1 study of NTLA-2001 in hereditary transthyretin amyloidosis with polyneuropathy and transthyretin amyloid cardiomyopathy has complete…
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India
A completed clinical trial in India studied Tafamidis for transthyretin amyloid cardiomyopathy. The study was sponsored by Pfizer.
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
A clinical trial update indicates completion of a study evaluating tafamidis 61 mg in people with transthyretin amyloid cardiomyopathy.
-
CLINICAL_TRIALS trial_result · 2025-08-03Clinical Trial Update: Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy [Phase 1]
Phase 1 clinical trial evaluating parametric cardiac 18F-flutemetamol PET imaging in transthyretin amyloid cardiomyopathy has completed.
-
CLINICAL_TRIALS trial_result · 2025-05-08Clinical Trial Update: Vyndaqel Capsules Special Investigation (ATTR-CM)
Pfizer reports the completion of a special investigation trial evaluating Vyndaqel (tafamidis) capsules for transthyretin amyloid cardiomyop…
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy [Phase 3]
This clinical trial update reports the completion of a Phase 3 long-term safety evaluation of tafamidis in transthyretin amyloid cardiomyopa…
-
CLINICAL_TRIALS trial_result · 2025-01-29Clinical Trial Update: carDIo-ttranSSfOrm nucLEar Imaging Study
The carDIo-ttranSSfOrm nucLEar Imaging Study, sponsored by Oregon Health and Science University, has been terminated. The study involves amy…
-
CLINICAL_TRIALS trial_result · 2024-12-18Clinical Trial Update: A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) [Phase 4]
Pfizer completed a Phase 4 study evaluating the safety and efficacy of tafamidis in Chinese participants with transthyretin amyloid cardiomy…
-
CLINICAL_TRIALS trial_result · 2024-12-16Clinical Trial Update: A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM [Phase 3]
Phase 3 trial of ALXN2060 in Japanese participants with symptomatic transthyretin amyloid cardiomyopathy has completed and results were post…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10 [Phase 1]
Phase 1 single and multiple ascending dose study assessing safety, tolerability, PK and PD of AG10 in transthyretin amyloid cardiomyopathy; …
-
CLINICAL_TRIALS trial_result · 2024-08-06Clinical Trial Update: SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy [Phase 4]
Phase 4 clinical trial evaluating SGLT2 inhibitors in transthyretin amyloid cardiomyopathy has completed with results posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-07-19Clinical Trial Update: Global Prevalence of ATTR-CM in Participants With HFpEF [NA]
Pfizer-sponsored clinical trial evaluating how common transthyretin amyloid cardiomyopathy is among people with heart failure with preserved…
-
CLINICAL_TRIALS trial_result · 2024-06-27Clinical Trial Update: Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy [Phase 3]
Phase 3 trial of AG10 in transthyretin amyloid cardiomyopathy has been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed With Wild-Type Transthyretin Cardiac Amyloidosis [Phase 4]
Phase 4 clinical trial evaluating trimetazidine's impact on mitochondrial function, myocardial performance, and invasive hemodynamics in pat…
-
CLINICAL_TRIALS trial_result · 2021-01-05Clinical Trial Update: Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy [Phase 3]
Phase 3 trial update evaluating Fx-1006a in patients with ATTR-CM (TTR-CM) has completed, with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2020-12-04Clinical Trial Update: Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy [Phase 1, Phase 2]
Phase 1/2 trial investigating doxycycline and TUDCA in transthyretin amyloid cardiomyopathy has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-04-03Clinical Trial Update: Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy [Phase 3]
Phase 3 clinical trial assessing safety and efficacy of tafamidis in transthyretin cardiomyopathy has completed with results posted.